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AbstrACt: ulcerative colitis treatment intends to induce remission, and its maintenance. Biological drugs, such as infliximab, 
have been indicated in moderate and severe cases of the disease, which are unresponsive to conventional medication. Randomized 
controlled trials proved the efficacy of biological treatment with high rates of sustained disease remission and mucosal healing. Re-
cently, the concept of mucosal healing has been inversely associated with surgical treatment. Patients treated with infliximab have 
lower colectomy rates than those receiving conventional therapies. We suppose that earlier use of biological drugs in disease’s course 
would lead to better clinical control and mucosal healing, with a consequent reduction in colectomy rates. To support this hypothesis, 
a literature review from January, 1996 to April, 2011 was performed. 
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IntrOduCtIOn 
The treatment of inflammatory bowel disease (IBD) 
has dramatically changed since the introduction of bio-
logical medications, especially the monoclonal antibod-
ies against tumor necrosis factor (anti-TnFα). The main 
anti-TNF drugs used in clinical practice are: infliximab, 
adalimumab, and more recently certolizumab pegol1-13.
The pro-inflammatory cytokine TNF-α plays an 
important role in the inflammatory process of IBD, 
mainly in Crohn’s disease. However, its role in the 
pathogenesis of non-specific ulcerative colitis (UC) is 
still an issue of debate1-4. 
The clinical control of uC patients is based on 
salicylate therapy, such as sulphasalazine and mesala-
zine. in refractory cases, most authors recommend im-
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munomodulators. steroid treatment is only indicated 
for a few weeks in the remission induction, but it is 
not suggested for remission maintenance. The main 
objective of medical treatment is to induce and main-
tain disease remission, avoiding flare-ups and the need 
for steroids. remission maintenance of the disease is 
inversely associated with indication of a surgical pro-
cedure, such as total colon removal and ileal pouch 
anal anastomosis (iPaa)5-10. even so, despite clinical 
treatment, around 9% of patients with distal colitis and 
35% of those with diffuse colitis (pancolitis) under-
go surgery and have their colons removed during the 
course of the disease5-10.
several pilot studies have been performed using 
anti-TNF, especially infliximab, with the aim of treat-
ing patients with UC unresponsive to conventional 
medication1-4. The most important study in this topic 
was published in 20055. Two recent randomized, con-
trolled and double-blinded trials with UC patients de-
nominate aCT 1 and aCT 2 (active Colitis Trial 1 
and 2) demonstrated the efficacy of infliximab for in-
duction and maintenance of remission in patients with 
moderate to severe uC not responding to conventional 
treatment5. More than 60% of the patients included in 
this study who received infliximab achieved disease 
remission and intestinal mucosa healing5. Jarnerot et 
al.6, reported that infliximab can be used as a rescue 
therapy in patients with moderate to severe persistent 
UC, which is associated with significant reduction 
colectomy rates.
We wondered whether earlier use of biological 
therapy during disease course, as well as being used in 
treating Crohn’s disease – top-down approach – could 
lead to better clinical control and mucosa healing, 
with a consequent reduction in colectomy rates12-13. To 
support this hypothesis, a wide literature review was 
carried out to find better evidence over a period from 
January, 1996 to april, 2011.
InFLIXIMAb And uC 
since the beginning of this decade, anti-TnFs, es-
pecially infliximab, have been used in the treatment of 
moderate to severe uC resistant to conventional treat-
ment. sands et al.2 published one of the first studies re-
garding using infliximab in patients with UC. Those 
who received infliximab presented clinical and endo-
scopic improvement compared to the Placebo Group, 
but without statistical significance. Amongst the initial 
60 patients planned for inclusion, only 11 were ran-
domized: 3 received placebo and the others, different 
infliximab doses. All three placebo patients had colec-
tomies at the end of the study and among the eight re-
ceiving infliximab, only four underwent surgery2.
Jarnerot et al.6, in a multicenter scandinavian 
study, evaluated the efficacy of infliximab as a res-
cue therapy in patients with UC resistant to conven-
tional drugs and indicated for colectomy. Forty-five 
patients were included (24 treated with infliximab 
and 21 with placebo). Twenty-nine per cent (7/24) of 
infliximab patients were submitted to surgery, while 
67% of the Placebo Group (14/21) had their colons 
removed due to lack of response. This was the first re-
port in literature with strong evidence supporting the 
use of infliximab as a rescue therapy before colectomy 
indication5. in a multicenter retrospective study per-
formed in italy, Kohn et al.10 reported infliximab use 
in 83 patients with an acute moderate or severe epi-
sode of uC indicated for colectomy, due to resistance 
to intravenous corticosteroids. as a rescue therapy be-
fore colectomy, all patients received between one and 
three doses of infliximab (5 mg/kg) every two or four 
weeks, without any pre-established protocol. Those 
who did not respond to treatment were submitted to 
colectomy. Eighty-two per cent avoided colectomy at 
two months. Sixty-one patients (73%) reached clini-
cal remission at one month. seventy patients (84%), 
who attained the primary endpoint (no colectomy or 
death), were followed-up for a median period of 23.4 
months. Over this period, 97% patients discontinued 
glucocorticoids. There was a total of 12 (29%) colec-
tomies among the 83 patients included in the study10.
rutgeerts et al.5 performed a randomized, con-
trolled, double-blinded, clinical study – aCT-1 and 
ACT-2. They reported about the efficacy of inflix-
imab in patients with moderate and severe UC resis-
tant to conventional therapy with corticosteroids and 
immunomodulators5. in a recently published post-hoc 
analysis of aCT-1 and aCT-2, sandborn et al.9 ob-
served 41% reduction risk of colectomy in the Inflix-
imab Group during the treatment period of 54 weeks. 
The objective of this post-hoc analysis was to estab-
lish whether infliximab could reduce the number of 
colectomies over a one-year period. Treatment with 
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this biologic led to a 7% reduction in absolute risk 
of colectomy. This was statistically significant in pa-
tients treated with 10 mg/kg infliximab (18/242, 8%, 
p=0.0007), but it was not statistically significant in pa-
tients treated with 5 mg/kg (28/242, 12%, p=0.166), 
when compared to placebo (36/242, 17%)5,9.
InFLIXIMAb, MuCOsAL HEALInG, 
And COLECtOMY
Currently, the main purpose of treating Crohn’s 
disease is to promote intestinal mucosal healing12. 
There is no question regarding intestinal healing as 
the main predictive factor related to long-term clini-
cal remission12,14,15. in analogy to Crohn’s disease, the 
early use of biological drugs since disease diagnosis – 
top-down therapy – could also lead to improved intes-
tinal healing rates for UC patients with the consequent 
long-term control of symptoms12,13. 
A Norwegian, population-based, cohort study of 
uC patients reported that mucosal healing after one 
year of treatment was associated with low risk of fu-
ture colectomy16. a population-based cohort of 843 
incident cases of IBD in Norway was collected from 
1990 to 1994 and subjected to a scheduled prospec-
tive follow-up, with a one-year visit and a five-year 
visit. Data from a total of 513 incident uC patients 
were available from the inflammatory bowel disease 
in Southeastern Norway (IBSEN) study. After exclu-
sion of patients undergoing colectomy during the first 
year after diagnosis (n=15), and some patients who 
did not meet follow-up criteria, 448 patients with UC 
were eligible for the one-year follow-up. Of the pa-
tients with mucosal healing at the one-year follow-up, 
three were recorded as having undergone surgery at 
five years, compared with 13 in the group without mu-
cosal healing at one year (p=0.02).
Moreover, multiple logistic regression analyses 
were performed with mucosal healing or endoscopic 
inflammatory activity as the dependent variable and 
different subsets of variables. only educational level 
and disease extension (proctitis, proctosigmoiditis, left 
sided, extensive colitis) were recognized as significant 
mucosal healing predictors (p=0.004 and p=0.02, re-
spectively). The authors concluded that, indeed, there 
is a relationship between disease’s extension and mu-
cosal healing as a result of more aggressive treatment 
in patients with extensive colitis16. Furthermore, in 
an univariate analysis, it was found a positive rela-
tionship between mucosal healing and fever at base-
line in patients with Crohn’s disease and also by the 
significant predictive role of other symptoms, such as 
pain on subsequent mucosal healing16. 
indeed, this fact supports the hypothesis and it 
allows us to speculate that, maybe, patients with ex-
tensive disease or severe symptoms may have been 
treated earlier and more aggressively. The authors 
suggested that we must adopt a strategy for the ear-
liest possible treatment in both children and adults. 
such strategy can reduce hospitalization and surgery 
costs and may prevent complications and disability at 
a young age16.
The natural history of inflammatory intestinal 
diseases can be changed if we adopt an effective treat-
ment, which heals intestinal mucosa12,16. recently, a 
Swedish/Danish group published the long-term effi-
cacy of infliximab as a rescue therapy in severe UC 
patient7. The ones who participated in the first study 
published in 2005 were followed-up for a median of 
55 months (range 36 to 79 months)6-7. in the original 
study, patients with severe UC were randomized to re-
ceive a single infusion of infliximab or placebo, and 
colectomy rates were measured after 90 days6. Patients 
of the same cohort were followed-up for three years. 
Additional anti-TNF therapy was allowed for clinical 
relapse. Clinical remission was defined as total Mayo 
score ≤1 and endoscopic remission as Mayo endoscop-
ic subscore=05,7. eleven of 15 patients that did not un-
dergo surgery at follow-up were in clinical remission 
and 12 of 15 patients not operated were in endoscopic 
remission. Fifty percent (7/14) of the patients who had 
their colon removed were not in endoscopic remission 
in the moment of operation. on the other hand, none 
(0/8) of the patients in endoscopic remission was op-
erated. after three years, the authors reported a sig-
nificant reduction in colectomy rates observed in the 
first study6. Fifty percent (12/24) of the patients treat-
ed with infliximab were operated compared to 76% 
(16/21) treated with placebo (p=0.012)7.
The anti-TnF drugs used in Crohn’s disease 
and uC therapy intend to the macroscopic heal-
ing of the intestinal mucosa (absence of erosion and 
ulcers)12,14,15,17. Also, infliximab is associated with an 
improvement of inflamed tissue ultra-structure17. Fra-
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rEsuMO: O tratamento da colite ulcerativa tem como objetivo induzir a remissão, além da manutenção da remissão da doença. 
Agentes biológicos como o infliximabe têm sido indicados em casos moderados e graves da doença, os quais não respondem à medi-
cação convencional. Ensaios clínicos randomizados comprovaram a eficácia do tratamento biológico com altas taxas de remissão da 
doença e cicatrização sustentada da mucosa. Recentemente, o conceito de cicatrização da mucosa tem sido inversamente associado 
com o tratamento cirúrgico. Pacientes tratados com infliximabe têm taxas mais baixas de colectomia se comparados com aqueles que 
receberam terapias convencionais. Supõe-se que quanto mais cedo for introduzida a terapia biológica no curso da doença, melhor 
seriam o controle clínico e a cicatrização da mucosa, com consequente redução nas taxas de colectomia. Para apoiar esta hipótese, foi 
realizada uma revisão da literatura entre janeiro de 1996 e abril de 2011.
Palavras-chave: terapia biológica; colectomia; colite ulcerativa; resultado do tratamento. 
tila and Craciun17 reported intracellular improvement 
in the mucosa of UC patients treated with infliximab. 
Four weeks after receiving two infusions of infliximab 
(5 mg/kg) – weeks 0 and 2 –, patients were submitted 
to colonoscopy and inflamed colon mucosa biopsy. An 
important intracellular improvement was seen after 
infliximab treatment. The authors reported improve-
ment in the morphology and function of the epithe-
lial organelles, rich mucus secretion, and recovery of 
the chorionic components. at the end of treatment, the 
new ultra-structural assessment clearly showed signs 
of epithelial barrier recovery, with appearance of the 
goblet cells, microvillus border, Golgi complex, and 
mitochondria, resulting in a general aspect of tissue 
healing. The metabolic activity and the energetic func-
tion were re-engaged due to numerous vesicles syn-
thesized in the cytoplasm and electron-dense normal 
mitochondria17. 
Therefore, it is evident that treatment with bio-
logical drugs promotes an improvement in clinical 
symptoms, and macroscopic (endoscopy) and micro-
scopic mucosa healing, including the cellular level17. 
Such findings may indicate a change in the disease’s 
natural history. 
At present, unfortunately, there is no scientific 
evidence that support the theory that top-down ap-
proach in UC patients would be better than conven-
tional treatment. However, in patients with moderate 
to severe UC, it has shown higher rates of mucosal 
healing when comparing infliximab to convention-
al therapy5. Therefore, it is pertinent to speculate 
whether patients treated early with infliximab and 
who received a regular maintenance dose every two 
months, would have healed colon, and in the long-
term, reduced number of complications and lower 
probability of colectomies. 
COnCLusIOns
Anti-TNF biological drugs are a landmark in 
the treatment of inflammatory bowel disease, espe-
cially infliximab and adalimumab5-11,13-22. The an-
ti-TNFs promote healing of the inflamed intestinal 
mucosa with reduction in the local inflammatory 
process, erosions, and ulcerations5,16. also, the use of 
infliximab in UC can lead to the ultra-structural im-
provement in inflamed cells17. such macroscopic and 
ultra-structural changes observed in intestinal mu-
cosa after treatment with anti-TNFs were defined in 
literature as mucosal healing. Healing of the mucosa 
is directly associated with the reduction in number of 
colectomies in UC patients who received anti-TNF 
therapy7-10,16,20-22. Finally, just as we see a modifica-
tion in the natural history of Crohn’s disease, patients 
who receive early biological – top down therapy 
–have sustained disease remission, fewer relapses, 
fewer hospitalizations, and consequent reduction in 
intestinal surgery, we believe that the UC patients 
could also have the same favorable clinical evolution 
if treated early with biological therapy12,16.
ACKnOWlEDgmEnT
The authors thank Juliana Interdonato and Co-
lin Knaggs for medical writing and for polishing the 
english language.
Biological therapy in the treatment of moderate-to-severe ulcerative colitis patients: 
can colectomy be prevented? 
Fábio Vieira Teixeira et al.
329
Journal of Coloproctology
October/December, 2011
Vol. 31
nº 4
rEFErEnCEs
1. Evans RC, Clarke L, Heath P, Stephens S, Morris AI, Rhodes 
JM. Treatment of ulcerative colitis with an engineered human 
anti-TNFalpha antibody CDP571. Aliment Pharmacol Ther. 
1997;11:1031-5.
2. sands Be, Tremaine WJ, sandborn WJ, rutgeerts PJ, 
Hanauer SB, Mayer L, et al. Infliximab in the treatment of 
severe, steroid-refractory ulcerative colitis: a pilot study. 
Inflamm Bowel Dis. 2001;7:83-8. 
3. Probert Cs, Hearing sD, schreiber s, Kühbacher T, 
Ghosh S, Arnott ID, et al. Infliximab in moderately severe 
glucocorticoid resistant ulcerative colitis: a randomised 
controlled trial. Gut. 2003;52:998-1002.
4. Ochsenkühn T, Sackmann M, Göke B. Infliximab for acute, 
not steroid-refractory ulcerative colitis: a randomized pilot 
study. Eur J Gastroenterol Hepatol. 2004;16:1167-71.
5. rutgeerts P, sandborn WJ, Feagan BG, reinisch W, olson 
A, Johanns J, et al. Infliximab for induction and maintenance 
therapy for ulcerative colitis. n engl J Med. 2005;8; 
353:2462-76.
6. Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen 
P, Granno C, et al. Infliximab as rescue therapy in severe to 
moderately severe ulcerative colitis: a randomized, placebo-
controlled study. Gastroenterology. 2005;128:1805-11.
7. Gustavsson A, Järnerot G, Hertervig E, Friis-Liby I, 
Blomquist L, Karlén P, et al. Clinical trial: colectomy after 
rescue therapy in ulcerative colitis - 3-year follow-up of 
the Swedish-Danish controlled infliximab study. Aliment 
Pharmacol Ther. 2010;32:984-9.
8. aratari a, Papi C, Clemente V, Moretti a, luchetti r, Koch 
M, et al. Colectomy rate in acute severe ulcerative colitis in 
the infliximab era. Dig Liver Dis. 2008;40:821-6.
9. sandborn WJ, rutgeerts P, Feagan BG, reinisch W, olson 
a, Johanns J, et al. Colectomy rate comparison after 
treatment of ulcerative colitis with placebo or infliximab. 
Gastroenterology. 2009;137:1250-60.
10. Kohn a, Daperno M, armuzzi a, Cappello M, Biancone l, 
Orlando A, et al. Infliximab in severe ulcerative colitis: short-
term results of different infusion regimens and long-term 
follow-up. Aliment Pharmacol Ther. 2007;26:747-56. 
11. Gies N, Kroeker KI, Wong K, Fedorak RN. Treatment of 
ulcerative colitis with adalimumab or infliximab: long-term 
follow-up of a single-centre cohort. Aliment Pharmacol Ther. 
2010;32:522-8. 
12. Baert F, Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, 
De Vos M, et al. Mucosal healing predicts sustained clinical 
remission in patients with early-stage Crohn’s disease. 
Gastroenterology. 2010;138:463-8.
13. Teixeira FV, Saad-Hossne R, Carpi MR, Teixeira ACA, 
Teixeira Jr P. Infliximab: First line therapy in ulcerative 
colitis. Preliminary report.  J Coloproctol. 2008;28:289-93.
14. lichtenstein Gr, rutgeerts P. importance of mucosal 
healing in ulcerative colitis. Inflamm Bowel Dis. 2010; 
16:338-46. 
15. Rubin DT, Huo D, Hetzel JT, Bunnag AP, Sedrak M, Hart JA, 
et al. Increased degree of histological inflammation predicts 
colectomy and hospitalization in patients with ulcerative 
colitis. Gastroenterology. 2007;132(Suppl 2):A19.
16. Frøslie KF, Jahnsen J, Moum Ba, Vatn MH; iBsen Group. 
Mucosal healing in inflammatory bowel disease: results from 
a Norwegian population-based cohort. Gastroenterology. 
2007;133:412-22.
17. Fratila OC, Craciun C. Ultrastructural evidence of mucosal 
healing after infliximab in patients with ulcerative colitis.  J 
Gastrointestin Liver Dis. 2010;19:147-53.
18. schirbel a, reichert a, roll s, Baumgart DC, Büning C, 
Wittig B, et al. Impact of pain on health-related quality of 
life in patients with inflammatory bowel disease. World J 
Gastroenterol. 2010;16:3168-77.
19. Meyer AL, Teixeira MG, de Almeida MG, Kiss DR, 
Nahas SC, Cecconello I. Quality of life in the late follow-
up of ulcerative colitis patients submitted to restorative 
proctocolectomy with sphincter preservation over ten years 
ago. Clinics (Sao Paulo). 2009;64:877-83.
20. Caviglia r, ribolsi M, rizzi M, emerenziani s, 
Annunziata ML, Cicala M. Maintenance of remission with 
infliximab in inflammatory bowel disease: efficacy and 
safety long-term follow-up. World J Gastroenterol. 2007; 
13:5238-44.
21. russo ea, Harris aW, Campbell s, lindsay J, Hart a, arebi 
N, et al. Experience of maintenance infliximab therapy for 
refractory ulcerative colitis from six centres in England. 
aliment Pharmacol Ther. 2009;29:308-14. 
22. Travis sP, Higgins PD, orchard T, Van Der Woude CJ, 
Panaccione R, Bitton A, et al. Review article: defining 
remission in ulcerative colitis. aliment Pharmacol Ther. 
2011;34:113-24.
Correspondence to: 
Fábio Vieira Teixeira
Avenida Maria Cecília Alves, 268 – Parque das Esmeraldas 
CEP: 17516-660 – Marília (SP), Brazil
E-mail: fabioteixeira@unimedmarilia.com.br 
